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Apigenin is a naturally occurring plant flavone with prominent 
antioxidant and anti-inflammatory properties. Although apigenin has the 
potential to be a promising molecule also for cancer treatment, its 
delivery to the body requires suitable dosage form design due to 
physicochemical characteristics that lead to poor bioavailability. It is 
classified as a BCS (Biopharmaceutical Classification System) II drug 
with low water solubility and high lipophilicity. 
Improving the solubility of apigenin is crucial, various formulation 
approaches have recently been employed e.g. nanocrystals have increased 
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dissolution rate and antioxidant activity, while polymeric micelles 
increased the solubility to 148 times higher than that crude apigenin and 
showed enhanced cytotoxicity on hepatoma cells. PLGA encapsulated 
apigenin nanoparticles cause mitochondrial apoptosis and even DNA 
targeting could be achieved in skin cancer. 
The chapter reviews current approaches to the formulation of drug 
delivery systems containing apigenin. 
 
 
NATURAL SOURCES, INTAKE AND PHARMACOLOGY 
 
Apigenin is a 4',5,7-trihydroxyflavone (Figure 1) belonging to a vast 
group of polyphenolic compounds called flavonoids. Flavonoids occur 
ubiquitously in the plant kingdom as secondary metabolites. They have a role 
in plant physiology, especially in pigmentation and flavor and also provide 
resistance against pathogens and insects. Six subclasses of flavonoids are 
distinguished - namely flavones, flavonols, flavanones, catechins, 
anthocyanidins and isoflavones - that have hydroxyl and phenolic groups 
variously attached to the common diphenylpropane structure (C6-C3-C6) 
(Ross and Kasum 2002). Generally one or more sugar components are linked 
to the aglycon molecule with O- or C-glycosidic bond in plants. Thus 
flavonoids are presented widely as glucosides in food but they are known to 
demonstrate incomplete absorption. They are abundantly distributed in fruits, 
vegetables and beverages with plant origin such as wine and tea. The average 
daily intake of flavonoids in a normal diet is approximately 1-2 g (Havsteen 
2002). In the Hungarian population the total flavonoid intake was estimated to 
be 18.80 mg with only 0.58 mg apigenin (Lugasi, Hóvári et al 2003). Many 
mechanisms of action have been identified for flavonoids, including 
antioxidant activity (Prochazkova, Bousova et al. 2011), changes in cellular 
signaling, apoptosis induction, anti-proliferation and anti-inflammation (Birt, 
Hendrich et al. 2001), thus suggesting their potential in cancer prevention. The 
use of pure flavonoids as a treatment in many common diseases such as 
cardiovascular and gastrointestinal disorders is increasing. Researchers have a 
growing interest in natural active ingredients to prevent or treat cancer, since 
most drugs currently available in the market have several disadvantages, being 
very toxic, highly inefficient or highly expensive. Unfortunately, the 
apparently effective concentrations of polyphenols in vitro are often higher 
than the absorbed amount measured in vivo. 
Apigenin can be found in a variety of fruits and vegetables (Peterson and 
Dwyer 1998). 
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Figure 1. Chemical structure of apigenin and its glycosides. 
The main sources of apigenin are celery, parsley, onion and chamomile, 
and it is present mainly in glycosides (Database 2014, May). However it 
occurs in a very low amount in the human diet (Meyer, Bolarinwa et al. 2006). 
It is recognized that apigenin has many pharmacological activities like free 
radical scavenging (Horvathova, Novotny et al. 2003, Škerget, Kotnik et al. 
2005) and anti-inflammatory activities (Funakoshi-Tago, Nakamura et al. 
2011, Choi, Islam et al. 2014). Furthermore, it has anticancer effects via 
modifying cell signaling pathways (Patel, Shukla et al. 2007, Shukla and 
Gupta 2010) in several tumor cell lines including skin (Wei, Tye et al. 1990, 
Tong, Van Dross et al. 2007, Abu-Yousif, Smith et al. 2008), breast (Yin, 
Giuliano et al. 2001), colon (Wang, Heideman et al. 2000, Chunhua, Donglan 
et al. 2013) and pancreas (Lefort and Blay 2013, Wu, Yu et al. 2014). Recent 
clinical studies suggest that a diet high in apigenin could potentially reduce the 
incidence of ovarian cancer in women (Gates, Vitonis et al. 2009). 
All of these findings indicate that apigenin is a very promising drug 
candidate against cancer and several other diseases. However, the 
physicochemical and biopharmaceutical properties reveal limited clinical use 
highlighting a need to develop new drug delivery systems. 
 
 
PHYSICOCHEMICAL PROPERTIES AND BIOAVAILABILITY 
 
Apigenin was classified as a drug belonging to BCS II. group 
(Biopharmaceutical Classification System) in a recent study (Zhang, Liu et al. 
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2012). This indicates high permeability but low solubility: the log P value is 
2.87 (Li, Robinson et al. 1997), but the aqueous solubility is very poor either 
in water (1.35 µg/mL) (Li, Robinson et al. 1997) or in buffers. The highest 
solubility value was at pH=7.5 (2.16 µg/mL) (Zhang, Liu et al. 2012) leading 
to poor intestinal absorption. Several studies have reported that the solubility 
of flavonoids depends on temperature, nature of solvents, pH conditions, as 
well as the thermodynamic properties of the compounds which allow 
formation of hydrogen bonds with the surrounding solvent (Saidman, 
Yurquina et al. 2002, Tommasini, Raneri et al. 2004, Xiao, Shao et al. 2011). 
The bioavailability of these molecules has been shown to be influenced by 
their chemical form in foods, the food matrix, and the consumer’s microbial 
flora (Birt, Hendrich et al. 2001). Apigenin could be detected in human plasma 
following ingestion of apigenin-rich food, but in a very low amount. The first 
pass metabolism in the small intestine and the liver in conjunction with 
enterohepatic recycling may play an important role in the poor systemic 
bioavailability observed (Chen, Lin et al. 2003). Several other factors can 
cause low bioavailability, including low solubility and dissolution rate, poor 
membrane permeation, rapid metabolism and elimination. Very less is known 
about the fate of apigenin in the body. 
Gastrointestinal tract is the main absorption site with both active and 
passive transport mechanism. This was confirmed with an intestinal transport 
study where apigenin could be detected in the whole intestine, with the main 
absorption site is probably being the duodenum. The mechanism might be 
passive transport in the ileum and colon segments with a concentration-
independent permeability, while in both the duodenum and jejunum segments 
an active carrier-mediated transport is involved with concentration-dependent 
permeability behavior (Zhang, Liu et al. 2012). It seems likely that apigenin in 
natural form bound to β-glycosides (apiin, apigetrin) provides better 
bioavailability, as the absorption of other flavonoid glycosides is generally 
more efficient than the absorption of aglycones. (Hollman P C 1996). This 
result is more likely because glycosides are water soluble forms of the aglycon 
and more stable, (e.g. against heating such as cooking), thus more glycosides 
can get to the body (Nielsen, Young et al. 1999). However, the sugar group 
makes the molecule quite polar (log P < 0), and therefore hindering cellular 
uptake and passage through the cell membrane (Walle and Walle 2002, Walle, 
Hsieh et al. 2004). It was thought that flavonoids could not absorb through the 
small intestine because glycosides can only be hydrolyzed by a β-glucosidase 
enzyme of microbial flora in the colon (Pekić, Zeković et al. 1994). However, 
recently three types of human β-glucosidase enzymes were discovered; one of 
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them capable of breaking the glycosidic bond and is located in the cells of the 
small intestine, liver and kidney (Asim 1993, Robert, Venkatakrishnan et al. 
1993, Berrin, Czjzek et al. 2003). In blood circulation, apigenin binds to the 
main carrier protein – human serum albumin (HSA) – with hydrophobic and 
electrostatic forces. It is noteworthy that there are several type of binding 
mode between apigenin and HSA, but most of them are very instable (Yuan, lv 
et al. 2007). 
 
 
DRUG DELIVERY APPROACHES 
 
In the last few decades the use of nutraceuticals to prevent chronic 
illnesses like diabetes, cardiovascular diseases and cancer has been rapidly 
emerging. These naturally occurring molecules possess antioxidant activity 
therefore can be effective against oxidative damage induced diseases. Various 
bioactive compounds from nutraceuticals and herbal medicines like flavonoids 
and other polyphenols have proven to be effective and have been applied with 
safe outcomes. Nevertheless, the exact dose and the complex mode of action 
are still unfolding areas (Nijveldt, van Nood et al. 2001). There is a need to 
investigate the influential factors on e.g. antioxidant activity during 
formulation development. 
In a recent study the antioxidant activity influenced by extraction process 
was measured. It was concluded that temperature and grinding have negative 
effect on antioxidant activity and flavonoid content, moreover the glucosides 
have lower antioxidant activity than aglycone (Pápay and Antal 2014). 
However, their low bioavailability in vivo limits their usage in medical therapy 
(Nijveldt, van Nood et al. 2001). Researcher’s attention has been drawn by 
nanotechnology which can change the pharmacokinetics and biodistribution 
thus improving the bioavailability and effectiveness (Huang, Yu et al. 2010). 
Controlled drug delivery systems makes targeted drug delivery possible thus 
leaving the healthy tissues unharmed and decrease the potential of side effects. 
This is extremely important in case of systematically administered 
chemotherapeutic agents that can cause severe side effects (Ferrari 2005, 
Merisko-Liversidge and Liversidge 2008). On the contrary, phytochemicals 
with anticancer properties have mild or negligible side effects. Several 
flavonoids including quercetin, luteolin and rutin were loaded into 
nanoparticles and have been found to be useful as nanomedicine (Nair, Sung et 
al. 2010). Solubility improvement of apigenin is crucial in order to achieve 
therapeutic effect as observed previously, and the delivery of apigenin requires 
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appropriate pharmaceutical formulation to provide protection of the 
therapeutically active molecular form until delivery to the target tissue. In the 
last decades a number of drug delivery approaches for apigenin have been 
developed, including the use of nanotechnology. 
 
 
Encapsulation into Inclusion Complexes and Colloidal Carriers 
 
Encapsulation into inclusion complexes or colloidal carriers may serve as 
technologies for enhancement of solubility and bioavailability. 
The molecular inclusion complexation can be achieved by using well 
known pharmaceutical solubilizers, namely cyclodextrins (CD). Natural CDs 
are consist of 6 (α), 7 (β), 8 (γ) glucopyranose units. These molecules are 
cyclic oligosaccharides made from starch by bacterial enzymatic conversion. 
They have truncated cone shape with hydrophobic cavity and hydrophilic rim 
due to the chair conformation of the units. They have the ability to form non-
covalent dynamic inclusion complexes with poorly water soluble drugs thus 
increasing their aqueous solubility, stability and bioavailability, especially for 
BCS II. and IV. drugs (Loftsson and Brewster 1996), (Szente and Szejtli 
1999). A number of data have been reported in the last years about the 
inclusion of plant materials (Pinho, Grootveld et al. 2014), but only one about 
the complexation of apigenin. Kim et al. investigated the aqueous solubility of 
apigenin with natural β-CD, its methylated (heptakis-(2,6-di-O-methyl)-β-
cyclodextrin, DM-β-CD) and hydroxylated (2-hydroxypropyl-β-cyclodextrin, 
HP-β-CD) derivates. The possible structure of complexation can be seen on 
Figure 2. The highest solubilization efficiency could be achieved with HP-β-
CD: 11.5 fold increase with 2 mM HP-β-CD compare to water. They also 
conducted phase solubility studies, where 1:1 stoichiometric flavonoid/CD 
complexation can be assumed from the plotted phase solubility diagrams. 
Stability constant (KC) values were the following: 827.6 with β-CD, 1038.6 
with DM-β-CD and 4511.5 with HP-β-CD. The strongest complexation occur 
with HP-β-CD, possibly due to hydrogen bonds between apigenin and 
hydroxyl groups (Kim H 2008). The degree of hydroxylation affects the 
hydrogen bonding capacity, and thus interactions with membrane (Ollila, 
Halling et al. 2002). 
For improving biological activity, apigenin can be encapsulated into 
liposomes or micelles, too (Figure 3). 
Lipid nanocapsules are patented biomimetric carriers which have 
characteristic hybrid structure of polymer nanocapsules and liposomes. 
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Figure 3. Encapsulation of apigenin into colloidal carriers. 
Lipid nanocapsules (LNC) were applied to encapsulate apigenin with 
phase inversion method. Generally medium-chain triglycerides build up the 
oily core which is surrounded by mixture of lecithin and pegylated surfactant 
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as a membrane. One of their advantages compared to liposomes the solvent 
free preparation process and longer stability, up to 18 months (Huynh, 
Passirani et al. 2009). The experiment was optimized by simplex lattice design 
experiment, for indexes drug loading and encapsulation efficiency was used. 
The optimal formulation resulted 1.26 ± 0.05% drug loading and 95.86 ± 
0.38% encapsulation efficiency. The total apigenin concentration was 5.88 
mg/mL with well dispersed, spherical in shape nanocapsules with average 
particle size 46.1 nm and -28.18 mV zeta potential. The in vitro release 
behavior showed two phase dynamics process and in vivo MTT assay showed 
enhanced antiproliferative activity. The study concluded that lipid 
nanocapsules are potential carrier for apigenin to improve its solubility and 





One of the studies was to investigate the influence of vehicle, distant 
topical delivery and biotransformation on chemopreventive activity of 
apigenin in mouse skin. Dorsal and abdomen skin of female SENCAR mice 
were treated and compared with apigenin in different model vehicles: DMSO, 
acetone/DMSO (4:1) and propylene glycol/DMSO (4:1). Apigenin showed to 
be effective in the order of DMSO> acetone/DMSO > propylene 
glycol/DMSO. Although most of these vehicles may not be suitable for human 
use, one of the goals of the study was to investigate whether apigenin can get 
into the blood circulation through the skin. The results suggested that apigenin 
permeate only locally to the skin tissues, with no transdermal permeation 
observed. The biotransformation experiments concluded that sulfate and 
glucuronide metabolites are not involved in the chemopreventive activity of 
apigenin (Li, Pinch et al. 1996). 
Incorporation of apigenin into a topical liposomal formulation showed 
success as substitutes for corticosteroid therapy in a clinical study. The 
apigenin-enriched, standardized chamomile extract were encapsulated into 
Natipide®II, a semi solid liposome gel, containing 20% of purified 
phospholipid fraction. The effectiveness of this formulation was compared to a 
non-liposomal oil-in-water cream, containing 5% Eumulgin® VL 75 as 
emulsifier. In vitro dissolution studies showed superior characteristics for 
liposomal creams. In vivo both were well tolerated and reduced inflammation, 
however, the liposomal formulation had slightly better therapeutic effect 
despite the same drug concentration. These results indicate that liposomes can 
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enhance the penetration into the skin and the formulation strategy has a great 
importance in therapeutic efficiency. Based on this clinical study, apigenin-
enriched formulations showed a great promise as a substitutes of corticosteroid 
therapy for e.g. eczema without severe side-effects (Arsic, Tadic et al. 2011). 
Drug delivery of apigenin into the skin is not only as an alternative but as 
a first choice treatment showed promising results against skin cancer. This 
disease is becoming resistant to conventional chemotherapy therefore 
improved drug delivery like mitochondria and DNA targeting is needed. In a 
recent study the efficacy of apigenin-loaded PLGA nanoparticles for 
mitochondrial targeting was tested (Das, Das et al. 2013). PLGA (poly (lactic-
co-glycolid acid) is a biodegradable, biocompatible and non-toxic material, 
one of the most successfully developed polymer. Its hydrolysis leads to two 
non-toxic metabolites: lactic acid and glycolic acid thus minimal toxicity is 
associated with the use of PLGA. It is approved by the FDA and European 
Medicine Agency for parenteral administration. Several formulations and 
methods of production for various drugs are well described. It is also able to 
protect the encapsulated drugs from degradation. Furthermore, sustained 
release and even specific organ or cell targeting can be achieved (Danhier, 
Ansorena et al. 2012). PLGA nanocarriers have the advantage of improving 
the permeability of the drug and showed enhanced delivery through mice skin. 
Thus, the aim of the study was to determine whether nano-encapsulated 
apigenin have greater anti-proliferative effect on UV-B and benzo(a)pyrene 
induced skin cancer in mice. Encapsulation was prepared using a one-step 
procedure of nanoprecipitation. Atomic force microscopy image showed that 
the majority of the particles are uniform and have spherical shape. The mean 
diameter was 101 nm with 87.2% encapsulation efficiency. Controlled release 
up to 72 h could be observed with a biphasic release profile characteristics, the 
initial burst release lasted for 16 hours. In order to determine the efficacy of 
nano-encapsulated apigenin histopathological sections and chromosomal 
aberrations were studied. Results showed that encapsulation improved the 
effectiveness due to small size and faster mobility; it reduced tissue damage 
and frequency of chromosomal aberrations. Moreover mitochondrial-apoptosis 
in cancerous tissues could be observed therefore nano-encapsulated apigenin 
appears to be promising in the skin cancer therapy (Das, Das et al. 2013). The 
same group found that PLGA nano-encapsulated apigenin had the ability to 
enter the nucleus thus directly target DNA. This suggests that PLGA 
nanoparticles can generate greater apoptotic effect and faster action and can 
prospectively be a new anti-cancer strategy in drug delivery to the skin (Das, 
Das et al. 2013). 
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Recently, a novel topical delivery system was developed for apigenin 
using ethosomes. This novel type of liposomes can enhance absorption and 
solubility due to 20-25 % (v/v) of lower alcohol content such as ethanol or 
propylene glycol. Their high deformability helps to transport the drug into the 
deeper layer of the skin more effectively than conventional liposomes. The 
optimal formulation was identified by uniform design experiment. Binary 
ethosomes were prepared to increase the stability and reduce aggregation using 
ethanol and propylene glycol. Lipoid S 75 (phosphatidylcholine containing 68-
73% of soybean lecithin) was chosen as lipid phase. To compare the 
effectiveness of ethosomes, empty ethosomes with external apigenin, 
conventional liposomes and deformable liposomes (containing Tween 80) 
were prepared with mechanical dispersion method. All formulations were 
loaded with 0.02% (w/v) apigenin. The volume ratio of the lower alcohols 
significantly affected the mean ethosome size. With increasing amount of 
propylene glycol the size increases or decreases with the total amount of 
alcohols. The particle size of the formulations ranged between 36.61 ± 1.78 
nm and 698.33 ± 124.30 nm, with zeta potentials between 10.14 ± 2.04 mV 
and 27.67 ± 3.23 mV. The optimum formulation had particle size distribution 
of 67.09 ± 4.10 nm with 19.30 ± 0.89 mV zeta potential. Entrapment 
efficiency of the optimum ethosomes was 91.22 ± 6.38 %, significantly higher 
than the other formulations 89.55 ± 1.57 % for liposomes and 81.93 ± 0.63 % 
for deformable liposomes. Increased level of Lipoid S 75 increased the 
entrapment efficiency of apigenin and the stability at room temperature for 30 
days. Skin deposition and transdermal efflux experiments were also 
conducted. Skin deposition measurement revealed that increasing amount of 
propylene glycol decreased the skin deposition of apigenin, however, this 
increased with higher amount of Lipoid S 75 and lower alcohol concentration 
in the formulation. High concentration of lower alcohols can positively 
influence the flexibility and fluidity of the ethosomes therefore increased 
deformability can enhance the penetration of the drug through stratum 
corneum. Considering these findings, the optimum formulation should consists 
of 5% Lipoid S 75 and a mixture of lower alcohols in the ratio of 1:10 (v/v) 
propylene glycol to ethanol. Transdermal efflux experiments showed similar 
result regarding the increased propylene glycol ratio to ethanol. Ethanol is a 
one of the most used penetration enhancer and co-solvent but it often causes 
excessive transdermal drug flux. Propylene glycol was therefore added to 
increase the viscosity, hygroscopicity and stability thus enhancing the 
accumulation into deep skin layers. Superior skin targeting could be achieved 
in vitro with these optimized ethosomes. This improved permeability of 
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apigenin into the skin is mostly related to the vesicle deformability and smaller 
particle size of ethosomes than conventional and deformable liposomes. 
Conventional liposomes did not penetrate deeply into the skin and in case of 
deformable liposomes the deposition of apigenin was even slower. However, 
there were number of differences between in vivo and in vitro skin deposition 
profiles, with ethosomes having the strongest effect on reducing inflammation 
induced by ultraviolet B (UVB) light. Ethosomes therefore can be a promising 
tool for superior topical delivery and targeting (Shen, Zhang et al. 2014). 
Apigenin nanocrystals were prepared also as a skin protective formulation 
against UVB. Nanosuspension or so-called nanocrystals - when the drug 
particles are in crystalline state - are nanosized and carrier free colloidal 
dispersions consisting of drug particles with only a small amount of stabilizer 
e.g. Plantacare 2000 UP® (alkyl polyglycoside). The main advantages of 
nanocystals are increased dissolution velocity and saturation solubility which 
results in increased concentration gradient between the formulation and the 
skin and therefore prolonged contact with the skin due to their adhesiveness 
(Müller and Peters 1998). Nanocrystals can be produced with “top-down” 
(reduce particle size) or “bottom-up” (growth of particles from molecules) 
technologies. The “top-down” technology e.g. wet milling or high pressure 
homogenization is widely used in pharmaceutical research because of the 
easier scale up for the industry. Since 2001, smartCrystals® technology has 
been used. Nanocrystals prepared with this combination technology (pre-
treatment step followed by high pressure homogenization step) show better 
characteristics e.g. physical stability. In this study the combination technology 
- bead milling and high pressure homogenization - was used to prepare 
apigenin smartCrystals. Significant reduction in size was observed after each 
bead milling process until the 5th passage therefore it was terminated after 7 
cycles, followed by low pressure (300 bar) homogenization step. Generally 
low pressure (100-500 bar) yields smaller and more homogenous nanocrystals. 
The photon correlation spectroscopy (PCS) diameter of the prepared 
nanocrystals was 396 ± 12 nm with 0.205 PdI ± 0.007. Low PdI indicates 
better physical stability. Light microscopy measurement showed uniform 
crystal distribution and no large crystals (>1µm) or aggregates could be 
detected. 1% of Plantacare 2000 UP® stabilizer provide optimal stability. Zeta 
potential measurements indicated well charged surface stability (-38 mV). X-
ray diffraction (XRD) revealed no amorphous stage which would reduce the 
stability and shelf life of the product. The developed smartCrystals can be 
easily utilized for further use as gel or cream where possibly a faster 
dissolution rate and increased permeation would be achieved. Furthermore, the 
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in vitro antioxidant capacity of the nanosuspension is doubled compared to the 





Orally administered apigenin has also a great potential in anticancer 
therapy but the extensive metabolism and poor aqueous solubility make it 
challenging. Nanocrystals can be further used to improve the oral 
bioavailability and also produce reproducible oral absorption. A new 
preparation method, SAS (supercritical antisolvent process) has been 
developed recently. This “bottom-up” process (recrystallization technology) 
requires no surfactant or other excipients and based on one kind of 
supercritical fluid technology. Briefly, the organic solution of the drug is 
injected into the supercritical fluid (generally CO2) and the drug precipitates as 
fine particles as the solvent get extracted and the drug solution gets 
supersaturated. 
The improved dissolution rate of the nanocrystals might be the key factor 
to increase the bioavailability and an effective formulation strategy for oral 
drug delivery (Zhang, Huang et al. 2013). Zhang et al measured the 
physicochemical and pharmacokinetic properties of the coarse powder and the 
prepared apigenin nanocrystals by SAS process. Morphological evaluation of 
the nanocrystals by scanning electron microscopy revealed regular shape and 
smooth surface with particle size of 400-800 nm. The mean particle size was 
determined to be 562.5 ± 56 nm with 0.92 ± 0.21 PdI according to PCS 
measurements. The crystals were mainly unaltered considering XRPD (X-ray 
powder diffractometry) and DSC (differential scanning calorimetry) analysis 
which means beneficial physicochemical stability. Moreover, FT-IR analysis 
showed that apigenin remained chemically stable during the process. 
Conducting in vitro dissolution studies, nanocrystals have higher dissolution 
platform (more rapid and higher cumulative amount) which can be attributed 
to the enhanced saturated solubility due to the reduced particle size. Only 40% 
of the coarse powder was dissolved in a 120 min study under sink conditions 
(0.1 M PBS 6.8 with 0.5% Polysorbate). In contrast more than 90% dissolved 
within 20 min, as apigenin nanocrystals, demonstrating good in vitro 
dissolution behavior. The plasma concentration of apigenin following 
intravenous administration in vivo decreased rapidly with time and followed a 
biphasic pattern due to the initial distribution and metabolism in the tissues. 
The formulation administered orally resulted much lower serum concentration, 
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but still higher than the coarse powder. The Cmax and AUC0-12 h were enhanced 
by 3.6 and 3.4 fold compared to apigenin coarse powder. The absolute 
bioavailability was enhanced from 2% up to 6.9%. It was concluded that 
nanocrystals with much smaller size and larger surface area can significantly 
improve the dissolution rate which contributes to higher Cmax and AUC0-12 h 
after oral administration. Furthermore, increased muco-adhesion and 
gastrointestinal transit time can be assumed. 
In another paper mixed TPGS (D-α-tocopherol acid polyethylene glycol 
succinate) modified phospholipid micelles were designed to increase the oral 
bioavailability of apigenin. The vesicular structure of the phospholipid 
complexes have limited stability therefore TPGS - a water soluble derivate of 
natural Vitamin E - was added. It is formed by the esterification of Vitamin E 
succinate with polyethylene glycol (PEG) and therefore contains a hydrophilic 
head (PEG) and a lipophilic tail (Vitamin E) like other surface active 
molecules. The relatively low CMC (0.02% w/w) makes it an ideal molecular 
biomaterial for developing liposomes and nanoparticles. It has been used as a 
solubilizer, stabilizer and absorption enhancer. It can prolong the half-life of 
the drug in the plasma and enhance cellular uptake but most importantly 
inhibits P-glycoprotein increasing oral delivery (Zhang, Tan et al. 2012). The 
apigenin-phospholipid-TPGS micelles were prepared with thin film hydration 
method. The 3D molecular modeling showed that apigenin was positioned in 
the hydrophobic chains of lecithin, directed to the glycerol moiety and 
similarly in the hydrophilic PEG chains of TPGS where intramolecular 
hydrogen bonds and electrostatic forces possibly play a role in the interaction. 
The 3D structures is shown on Figure 4. The computer model prediction - that 
PEG chains are directed to the surface of the micelle – is confirmed by the 
negative zeta potential data (-12.94 mV). The complexation with 
phospholipids was verified by FT-IR and NMR spectroscopy measurements 
while the interaction with TPGS was studied with surface tensiometry. The 
encapsulation efficiency was 87.35%, drug loading was 12.6% with 137.1±3.4 
nm particle size. In vitro release experiments showed an initial controlled 
release for 2 hours and the plateau was reached after 15 hours. Increased 
intestinal absorption up to 2.4 fold and higher cellular uptake with significant 
cytotoxicity effect on A549 cancer cell lines could be achieved. 
In vivo 72.9% inhibition in S180 carcinoma mice were observed. These 
results suggest that TPGS micelles combined with phospholipid complex 
technology can be a novel way for oral drug delivery (Munyendo, Zhang et al. 
2013). 
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Figure 4. TPGS (D-α-tocopherol acid polyethylene glycol succinate) modified 
phospholipid micelles to increase the oral bioavailability of apigenin. 
Oral liquid dosage forms are therefore usually preferred; self-
microemulsifying systems (SMEDDS) – a novel and promising technology for 
enhancing oral absorption has gained attention recently. SMEDDS contains 
oil, surfactant, co-surfactant and the drug. The drug can be solubilized in the 
oil phase and/or on the surface of the surfactant and co-surfactant in the 
microemulsion. Therefore the surfactant and co-surfactant play an important 
role in the solubilization of the drug. Mixing with water can produce 
thermodynamically stable oil-in-water microemulsion. The drug is dissolved 
in small droplets (size <100 nm) therefore the large surface area can enhance 
drug absorption (Pouton 2000). This system shows high drug entrapment and 
fast dissolution but the increase in the oral bioavailability is still needs to be 
estimated (Narang, Delmarre et al. 2007). 
Zhao et al investigated a self microemulsifying delivery system for 
apigenin, optimized by a simplex lattice experiment design. Ternary phase 
diagrams were also constructed from the excipients with high solubility of 
apigenin to obtain the most efficient concentration ranges for microemulsions. 
The apigenin exhibited the highest solubility in CapryolTM 90 oil (1.39 ± 0.03 
mg/mL), in Tween 80 surfactant (26.59 ± 1.16 mg/mL) and in Transcutol®HP 
co-surfactant (18.16 ± 0.43 mg/mL). The drug loading depends largely on drug 
solubility in the oil phase. The surfactant should be relatively hydrophobic 
(hydrophilic-lipophilic balance, HLB < 12) to obtain high self-
microemulsifying ability (immediate formation of o/w droplets) and forms 
stable microemulsion when diluted with aqueous media (Kohli, Chopra et al. 
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2010). Although Tween 80 exhibited the highest apigenin solubility, it could 
not form SMEDDS with Transcutol®HP and CapryolTM 90. PEG 400 was 
selected for the co-surfactant screening along with Transcutol®HP, however, 
its higher hydrophilic property could destroy the emulsion system. Finally, the 
optimal formulation consisted of 60% Cremophor®EL, 30% Transcutol®HP 
and 10% CapryolTM 90. 7500-fold increase in water solubility of apigenin 
could be achieved with 17.1 nm average particle size and zeta potential -5.18 
mV. The concentration of apigenin was selected to maximum 7 mg/g since at 
levels exceeding this apigenin precipitated during dilution with water. 
Transmission electron microscopy (TEM) images showed spherical droplets 
without agglomeration. 30 s was enough for the formation of microemulsion 
after dilution with distilled water and it did not precipitate after 8 hours (1 g of 
SMEDDS to 100 mL distilled water). The droplet size can be influenced by 
many factors and it plays an important role in the absorption. Interestingly, the 
size of this formulation was not affected by pH and ionic strength (diluted with 
distilled water, 0.9% NaCl, pH 6.8 PBS, 0.1 M HCl) and various mixing ways 
(vortex, magnetic stirring) but influenced by amount of apigenin. In vitro 
dissolution study demonstrated fast dissolution: 95 % of apigenin was released 
within 10 minutes. All of the results confirmed that SMEDDS could enhance 
the solubility of apigenin as a potential carrier for oral absorption (Zhao, 
Zhang et al. 2013). 
Nanosized polymeric micelles with particle size ranging from 10-100 nm 
have been recognized as a potential drug delivery systems for anticancer 
drugs. Their small size allows accumulation in cancerous tissues and 
prolonged circulation time without being recognized by reticuloendothelial 
system (RES). Conventionally, biocompatible and self-assembly amphiphilic 
block copolymers can form core-shell structure in aqueous media. The 
hydrophobic fraction is able to incorporate poorly water soluble drugs as a 
core while the hydrophilic chains crosslinking outside and form a shell (Croy 
and Kwon 2006). In a recent study apigenin was successfully loaded into 
polymeric micelles composed of Pluronic P123 and Solutol HS15, to improve 
its water solubility with a thin-film dispersion method (Zhai, Guo et al. 2013). 
Pluronic P123 is one of the most widely used triblock copolymer with a 
structure PEO-PPO-PEO. The hydrophobic PPO group comprises 70%, thus 
providing suitable microenvironment for hydrophobic drug while 30% PEO 
can form a relatively thin shell with reduced stability, necessitating further 
modifications (Schillen, Jansson et al. 2008). Solutol HS15 (polyethylene 
glycol-660 hydroxystearate) is recorded in the European Pharmacopoeia as a 
non-ionic solubilizing agent containing 30% of free polyethylene glycol 
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(PEG). In general, PEG used innanoformulations can increase stability and 
systemic circulation time (Vonarbourg, Passirani et al. 2006). The micelle 
formulations were optimized by central composite design. The solubility of 
apigenin was increased 148 times higher (320.8 µg/mL) than of crude apigenin 
(2.16 µg/mL) with low CMC concentration (4.23 x 10-5 mol/L) the following 
formulation: apigenin 1.68 mg, P123 92 mg and Solutol HS15 29 mg. The 
encapsulation efficiency and drug loading were 96.36% and 1.32 %. Under 
transmission electron microscope (TEM) the formulation had homogenous 
morphology. The size was 16.9 nm, smaller than blank micelles (18.9 nm), 
probably due to hydrogen bonds between phenolic hydroxyl group of apigenin 
and the carboxyl of the PEG chains. Moreover, in vitro drug dissolution study 
showed sustained release behavior and cytotoxicity studies on HepG2 and 
MCF-7 hepatoma cells demonstrated enhanced tumor inhibition (Zhai, Guo et 
al. 2013). 
The solubility behavior of an active ingredient is the most challenging 
aspect, therefore there is a constant demand for new type of drug carriers in 
oral formulation development. Although solid dispersions (SDs) are known 
since 1961, their application is still increasing with new types of dispersing 
carriers e.g. silica nanopowder. In these dispersions the drug is incorporated in 
an inert carrier in solid state. Sugar was used as a carrier in the first generation 
SD. Second generation SD utilized amorphous polymeric carriers e.g. PEG in 
the late sixties, and more recently self-emulsifying and high surface active 
carriers belong to third generation SD. These carriers are able to improve 
dissolution rate significantly by reducing particle size, amorphous drug state 
and enhanced wettability and porosity can be achieved avoiding drug 
crystallization. Optimized manufacturing techniques make easier scale-up 
possible for industrial research (Chiou and Riegelman 1971, Leuner and 
Dressman 2000, Vasconcelos, Sarmento et al. 2007). One new type of 
dispersing carrier is carbon nanopowder (CNP). This nanomaterial is built up 
from carbon with diameter of less than 100 nm. It has many unique features 
like large surface area, chemical inertness and high dispersibility which helps 
to improve drug dispersion, and are thus widely used in targeted drug therapy. 
CNP-Apigenin was prepared by solvent evaporation. Briefly, apigenin and 
CNP were dissolved in ethanol and evaporated in rotary evaporator at 40°C 
until a clear powder mixture was formed. In comparison a homogenous 
physical mixture was prepared by grinding using a mortar and pestle. In vitro 
drug release and in vivo performance were also evaluated from the solid 
dispersions of apigenin prepared with CNP. All of the CNP-Apigenin had 
better dissolution profiles than apigenin powder alone (only 38% was 
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dissolved). Approximately 92% of apigenin was released from the formulation 
with weight ratio 6:1 and the drug release dissolution profile was improved by 
275% within 60 minutes compared to crude apigenin powder. DSC 
thermogram did not show the peak of apigenin suggesting it is molecularly 
dispersed and may be in amorphous form, which facilitated the dissolution. 
Scanning electron microscopy confirmed that apigenin is dispersed in CNP 
while XRD patterns show amorphous state. Oral bioavailability was tested in 
rats. The pharmacokinetic analysis showed 1.83 times increase in the AUC0-t 
for CNP-Apigenin indicating improved bioavailability. The CNP-Apigenin 
enhanced the relative oral bioavailability by 183%. The in vivo tests were in 
accordance with in vitro data suggesting that the poor bioavailability can be 
attributed to poor dissolution and reduced absorption. Preliminary intestinal 
toxicity test was carried out on jejunum mucosa of rats and did not show any 
degeneration, necrosis, edema or inflammation. Therefore, it can be assumed 
that CNP are safe and effective vehicles to enhance bioavailability for poor 
water soluble drugs. Moreover, CNP-Apigenin did not agglomerate and 
flowed freely, making it possible to formulate on a large scale. It was 
concluded that CNP is a promising SD carrier for clinical application (Ding, 
Zhang et al. 2014). 
 
 
Dendrimers for Apigenin Delivery 
 
Dendrimers are polymeric macromolecules with hyperbranched three 
dimensional structures (Figure 5). Controlled, globular structure and a large 
number of functionalities yet single molecular weight are significantly 
advantageous over traditional linear polymers. These attracted researcher’s 
attention from the mid-1980s because of their unique shape and potential 
applications in drug delivery. Since then, a large number of dendrimers have 
been synthetized with various architectures. Two well documented synthetic 
strategies are used to prepare dendrimers, with the main difference being 
polymer growth (Hawker and Frechet 1990, Tomalia, Naylor et al. 1990). 
Basically, the polymer branches grow divergently or convergently start from a 
polyfunctional core (Liu and Fréchet 1999). A number of application are 
known for dendrimers. In the past decades biocompatible dendrimers were 
synthetized for drug delivery of e.g.vaccines and immunology. Recently, 
attempts have been made for cancer treatment and photodynamic therapy. 
Dendrimers can be useful tools as multifunction nanoparticulate systems for 
imaging, diagnostic and targeting in the therapy (Gillies and Fréchet 2005). 
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Figure 5. Internal cavities of the dendrimeric structure. 
They are a technological breakthrough and their use in nanotechnology is 
progressively emerging. Although accurate selection of dendrimers is a key 
factor in drug delivery they have a great potential as an optimal drug delivery 
system for numerous drugs including DNA, proteins, gene therapy as well as 
diagnostic and solubilizing agent (Kesharwani, Jain et al. 2014). Apigenin was 
chosen as a flourophore core of benzylic dendrimers in a recent study. 
Fluorescent dendrimers have an advantage as analytical tools or organic light 
emitting devices (OLEDs). Apigenin possess weak blue light emission and 
three phenol groups therefore ideal for synthetizing dendrimer according to 
Fréchet method (Hawker and Frechet 1990, Liu and Fréchet 1999). Size and 
branching effects were studied with molecular dynamics simulation. Data 
suggest that larger asphericities can occur at the third and fourth generations of 
dendrimers. Aggregation phenomena can be suggested for nonspheric 





Phytosome technology is a promising concept for enhancement of oral 
bioavailabilty. In water, phytosomes form liposome-like structure, however, 
there are significant differences (Kidd 2009, Semalty, Semalty et al. 2010). 
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The phytosome is a molecular complex consisting of the drug and 
phosphatidylcoline which later is compatible with biological membranes. The 
phospholipids are amphiphilic molecules and easily incorporate polar or non-
polar compounds, thus enhance the absorption through lipid-rich biological 
membranes. Since they can improve the bioavailability of both water soluble 






In the last few decades the use of nutraceuticals to prevent chronic 
illnesses like diabetes, cardiovascular diseases and cancer has been rapidly 
emerging. However, their low bioavailability in vivo limits their usage for 
medical therapy. Researchers are drawn towards nanotechnology which can 
change the pharmacokinetics and biodistribution thus improving the 
bioavailability and efficacy. Solubility improvement of apigenin is crucial in 
order to achieve therapeutic effect as discussed in the above section. The 
delivery of apigenin requires pharmaceutical formulation to provide protection 
of the therapeutically active molecular form until it reaches the target tissue. A 
few drug delivery approaches for apigenin have been developed in the past 
decades to address this issue, including novel techniques in the field of 
nanotechnology. The solubility behavior of an active ingredient – like apigenin 
– is still the most challenging part therefore there is a constant demand for new 
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